Trade Evotec AG - EVT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.110 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.022079% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000143% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 5% | ||||||||
Stock exchange | Germany | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Evotec SE ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Prev. Close* | 18.09 |
Open* | 18.335 |
1-Year Change* | 15.31% |
Day's Range* | 18.06 - 18.56 |
52 wk Range | 14.80-24.44 |
Average Volume (10 days) | 319.40K |
Average Volume (3 months) | 8.12M |
Market Cap | 3.40B |
P/E Ratio | -100.00K |
Shares Outstanding | 176.94M |
Revenue | 820.80M |
EPS | -0.54 |
Dividend (Yield %) | N/A |
Beta | 1.00 |
Next Earnings Date | N/A |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 8, 2023 | 18.260 | -0.080 | -0.44% | 18.340 | 18.595 | 18.005 |
Dec 7, 2023 | 18.090 | -0.470 | -2.53% | 18.560 | 18.560 | 18.090 |
Dec 6, 2023 | 18.800 | 0.515 | 2.82% | 18.285 | 18.895 | 17.985 |
Dec 5, 2023 | 17.945 | -0.160 | -0.88% | 18.105 | 18.350 | 17.765 |
Dec 4, 2023 | 18.195 | -0.120 | -0.66% | 18.315 | 18.960 | 18.105 |
Dec 1, 2023 | 18.330 | -0.285 | -1.53% | 18.615 | 18.700 | 17.910 |
Nov 30, 2023 | 18.535 | 0.155 | 0.84% | 18.380 | 18.560 | 18.030 |
Nov 29, 2023 | 18.265 | 0.340 | 1.90% | 17.925 | 18.325 | 17.850 |
Nov 28, 2023 | 17.645 | -0.325 | -1.81% | 17.970 | 18.045 | 17.645 |
Nov 27, 2023 | 18.175 | -0.430 | -2.31% | 18.605 | 18.920 | 18.115 |
Nov 24, 2023 | 18.845 | 0.150 | 0.80% | 18.695 | 18.885 | 18.560 |
Nov 23, 2023 | 18.725 | -0.275 | -1.45% | 19.000 | 19.035 | 18.385 |
Nov 22, 2023 | 19.045 | 0.395 | 2.12% | 18.650 | 19.135 | 18.610 |
Nov 21, 2023 | 18.765 | -0.370 | -1.93% | 19.135 | 19.160 | 18.610 |
Nov 20, 2023 | 19.165 | 0.730 | 3.96% | 18.435 | 19.275 | 18.265 |
Nov 17, 2023 | 18.635 | 0.545 | 3.01% | 18.090 | 18.815 | 18.090 |
Nov 16, 2023 | 18.225 | -0.435 | -2.33% | 18.660 | 18.940 | 18.200 |
Nov 15, 2023 | 18.585 | -0.115 | -0.61% | 18.700 | 18.965 | 18.335 |
Nov 14, 2023 | 18.625 | 1.075 | 6.13% | 17.550 | 18.735 | 17.410 |
Nov 13, 2023 | 17.270 | -0.080 | -0.46% | 17.350 | 17.705 | 17.270 |
Evotec AG Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 751.448 | 618.034 | 500.924 | 446.437 | 375.405 |
Revenue | 751.448 | 618.034 | 500.924 | 446.437 | 375.405 |
Cost of Revenue, Total | 577.383 | 466.491 | 375.181 | 313.546 | 263.389 |
Gross Profit | 174.065 | 151.543 | 125.743 | 132.891 | 112.016 |
Total Operating Expense | 724.824 | 588.901 | 452.368 | 383.843 | 297.942 |
Selling/General/Admin. Expenses, Total | 156.19 | 105.445 | 77.205 | 66.546 | 57.012 |
Research & Development | 76.642 | 72.2 | 63.945 | 58.432 | 35.619 |
Unusual Expense (Income) | -5.774 | 12.546 | 3.244 | 11.919 | -11.036 |
Other Operating Expenses, Total | -79.617 | -67.781 | -67.207 | -66.6 | -47.042 |
Operating Income | 26.624 | 29.133 | 48.556 | 62.594 | 77.463 |
Interest Income (Expense), Net Non-Operating | -179.854 | 208.106 | -22.925 | -6.102 | -5.602 |
Other, Net | -0.727 | -0.259 | 0.209 | 0.07 | 0.138 |
Net Income Before Taxes | -153.957 | 236.98 | 25.84 | 56.562 | 71.999 |
Net Income After Taxes | -175.655 | 215.51 | 6.278 | 37.228 | 84.056 |
Minority Interest | 0 | 0 | 0 | 0.844 | 0.116 |
Net Income Before Extra. Items | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Net Income | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Income Available to Common Excl. Extra. Items | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Income Available to Common Incl. Extra. Items | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Diluted Net Income | -175.655 | 215.51 | 6.278 | 38.072 | 84.172 |
Diluted Weighted Average Shares | 176.674 | 166.406 | 153.752 | 149.726 | 147.482 |
Diluted EPS Excluding Extraordinary Items | -0.99423 | 1.29509 | 0.04083 | 0.25428 | 0.57073 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -1.01547 | 1.36365 | 0.05455 | 0.30667 | 0.52209 |
Dilution Adjustment | 0 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 170.279 | 213.556 | 240.689 | 173.884 | 172.203 |
Revenue | 170.279 | 213.556 | 240.689 | 173.884 | 172.203 |
Cost of Revenue, Total | 123.956 | 160.319 | 158.233 | 145.464 | 141.308 |
Gross Profit | 46.323 | 53.237 | 82.456 | 28.42 | 30.895 |
Total Operating Expense | 206.567 | 201.041 | 197.229 | 187.413 | 175.973 |
Selling/General/Admin. Expenses, Total | 45.609 | 42.583 | 46.332 | 42.462 | 35.83 |
Research & Development | 12.377 | 18.486 | 21.322 | 18.482 | 18.725 |
Other Operating Expenses, Total | 24.625 | -20.347 | -22.884 | -18.995 | -19.89 |
Operating Income | -36.288 | 12.515 | 43.46 | -13.529 | -3.77 |
Interest Income (Expense), Net Non-Operating | 5.261 | -6.203 | -60.362 | -29.806 | -20.131 |
Other, Net | 10.59 | -12.527 | -0.622 | -0.029 | -0.435 |
Net Income Before Taxes | -20.437 | -6.215 | -17.524 | -43.364 | -24.336 |
Net Income After Taxes | -14.929 | -13.898 | -27.201 | -47.275 | -27.937 |
Net Income Before Extra. Items | -14.929 | -13.898 | -27.201 | -47.275 | -27.937 |
Net Income | -14.929 | -13.898 | -27.201 | -47.275 | -27.937 |
Income Available to Common Excl. Extra. Items | -14.929 | -13.899 | -27.201 | -47.275 | -27.937 |
Income Available to Common Incl. Extra. Items | -14.929 | -13.899 | -27.201 | -47.275 | -27.937 |
Diluted Net Income | -14.929 | -13.899 | -27.201 | -47.275 | -27.937 |
Diluted Weighted Average Shares | 176.936 | 176.936 | 176.589 | 176.703 | 176.703 |
Diluted EPS Excluding Extraordinary Items | -0.08438 | -0.07855 | -0.15404 | -0.26754 | -0.1581 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -0.08438 | -0.07855 | -0.17529 | -0.26754 | -0.1581 |
Unusual Expense (Income) | -5.774 | 0 | 0 | ||
Minority Interest | 0 | ||||
Total Adjustments to Net Income | -0.001 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 1073.67 | 1100.94 | 658.844 | 469.53 | 249.769 |
Cash and Short Term Investments | 729.983 | 858.498 | 492.634 | 321.662 | 149.879 |
Cash & Equivalents | 415.155 | 699.326 | 422.58 | 277.034 | 109.055 |
Short Term Investments | 314.828 | 159.172 | 70.054 | 44.628 | 40.824 |
Total Receivables, Net | 256.737 | 176.754 | 122.221 | 117.844 | 74.772 |
Accounts Receivable - Trade, Net | 199.169 | 150.692 | 91.612 | 93.702 | 58.851 |
Total Inventory | 29.825 | 25.793 | 13.585 | 10.749 | 5.66 |
Prepaid Expenses | 40.178 | 19.21 | 9.258 | 9.166 | 8.451 |
Other Current Assets, Total | 16.948 | 20.685 | 21.146 | 10.109 | 11.007 |
Total Assets | 2257.25 | 2235.16 | 1462.34 | 1180.91 | 771.883 |
Property/Plant/Equipment, Total - Net | 650.201 | 484.597 | 337.297 | 239.229 | 90.519 |
Property/Plant/Equipment, Total - Gross | 920.81 | 686.086 | 481.879 | 350.415 | 164.143 |
Accumulated Depreciation, Total | -270.609 | -201.489 | -144.582 | -111.186 | -73.624 |
Goodwill, Net | 274.819 | 257.569 | 247.37 | 255.919 | 220.791 |
Intangibles, Net | 23.819 | 30.851 | 98.036 | 116.994 | 122.989 |
Long Term Investments | 150.332 | 287.009 | 59.021 | 41.252 | 28.99 |
Note Receivable - Long Term | 70.293 | 55.966 | 36.485 | 22.718 | 14.601 |
Other Long Term Assets, Total | 14.112 | 18.229 | 25.284 | 35.27 | 44.224 |
Total Current Liabilities | 337.706 | 324.516 | 208.459 | 178.955 | 196.275 |
Accounts Payable | 97.277 | 72.598 | 42.549 | 31.319 | 31.137 |
Accrued Expenses | 47.49 | 33.983 | 34.728 | 29.174 | 25.67 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 16.381 | 50.609 | 30.008 | 20.731 | 56.919 |
Other Current Liabilities, Total | 176.558 | 167.326 | 101.174 | 97.731 | 82.549 |
Total Liabilities | 1070.06 | 857.476 | 737.881 | 703.883 | 347.879 |
Total Long Term Debt | 490.293 | 462.308 | 461.957 | 442.368 | 57.546 |
Long Term Debt | 328.295 | 326.344 | 331.019 | 324.886 | 54.68 |
Capital Lease Obligations | 161.998 | 135.964 | 130.938 | 117.482 | 2.866 |
Deferred Income Tax | 18.524 | 17.688 | 20.399 | 21.199 | 21.517 |
Minority Interest | 0 | 0 | 0 | 0 | 0.876 |
Other Liabilities, Total | 223.54 | 52.964 | 47.066 | 61.361 | 71.665 |
Total Equity | 1187.18 | 1377.69 | 724.456 | 477.029 | 424.004 |
Common Stock | 176.953 | 176.608 | 163.915 | 150.903 | 149.063 |
Additional Paid-In Capital | 1440.01 | 1430.14 | 1030.7 | 786.865 | 783.154 |
Retained Earnings (Accumulated Deficit) | -392.377 | -216.421 | -432.639 | -441.177 | -481.013 |
Unrealized Gain (Loss) | -21.113 | 3.053 | 4.26 | 4.565 | 6.002 |
Other Equity, Total | -16.289 | -15.691 | -41.782 | -24.127 | -33.202 |
Total Liabilities & Shareholders’ Equity | 2257.25 | 2235.16 | 1462.34 | 1180.91 | 771.883 |
Total Common Shares Outstanding | 176.703 | 176.358 | 163.665 | 150.653 | 148.813 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 939.198 | 1026.45 | 1073.67 | 1095.82 | |
Cash and Short Term Investments | 619.18 | 632.973 | 729.983 | 828.795 | |
Cash & Equivalents | 499.366 | 459.752 | 415.155 | 463.913 | |
Short Term Investments | 119.814 | 173.221 | 314.828 | 364.882 | |
Total Receivables, Net | 219.371 | 291.301 | 256.737 | 187.997 | |
Accounts Receivable - Trade, Net | 161.105 | 228.955 | 199.169 | 140.631 | |
Total Inventory | 31.906 | 32.612 | 29.825 | 30.874 | |
Prepaid Expenses | 68.741 | 69.563 | 57.126 | 48.15 | |
Total Assets | 2254.51 | 2301.22 | 2257.25 | 2262.66 | |
Property/Plant/Equipment, Total - Net | 763.899 | 721.136 | 650.201 | 600.499 | |
Goodwill, Net | 274.819 | 278.417 | |||
Intangibles, Net | 291.055 | 292.612 | 23.819 | 25.736 | |
Long Term Investments | 151.62 | 160.842 | 150.332 | 189.245 | |
Note Receivable - Long Term | 98.685 | 88.8 | 70.293 | 56.911 | |
Other Long Term Assets, Total | 10.052 | 11.382 | 14.112 | 16.039 | |
Total Current Liabilities | 434.045 | 488.107 | 337.706 | 340.802 | |
Accounts Payable | 96.774 | 106.038 | 97.277 | 83.965 | |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
Current Port. of LT Debt/Capital Leases | 144.287 | 151.638 | 16.381 | 14.108 | |
Other Current Liabilities, Total | 192.984 | 230.431 | 224.048 | 242.729 | |
Total Liabilities | 1113.69 | 1126.93 | 1070.06 | 1034.14 | |
Total Long Term Debt | 444.455 | 382.509 | 490.293 | 477.984 | |
Long Term Debt | 444.455 | 382.509 | 328.295 | 326.776 | |
Capital Lease Obligations | 161.998 | 151.208 | |||
Deferred Income Tax | 18.603 | 19.13 | 18.524 | 17.179 | |
Other Liabilities, Total | 216.587 | 237.188 | 223.54 | 198.173 | |
Total Equity | 1140.82 | 1174.29 | 1187.18 | 1228.53 | |
Common Stock | 177.186 | 177.186 | 176.953 | 176.953 | |
Additional Paid-In Capital | 1446.47 | 1445.36 | 1440.01 | 1437.55 | |
Retained Earnings (Accumulated Deficit) | -482.836 | -448.256 | -392.377 | -364.631 | |
Other Equity, Total | -16.289 | -21.348 | |||
Total Liabilities & Shareholders’ Equity | 2254.51 | 2301.22 | 2257.25 | 2262.66 | |
Total Common Shares Outstanding | 176.936 | 176.936 | 176.703 | 176.703 | |
Unrealized Gain (Loss) | -21.113 | ||||
Minority Interest | 0 | 0 | 0 | 0 | |
Other Current Assets, Total | 0.001 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -175.655 | 215.51 | 6.252 | 37.228 | 84.056 |
Cash From Operating Activities | 203.106 | 122.237 | 44.721 | 42.216 | 156.24 |
Cash From Operating Activities | 72.677 | 55.596 | 42.122 | 36.456 | 19.288 |
Amortization | 8.982 | 12.012 | 13.936 | 12.349 | 12.005 |
Deferred Taxes | 7.722 | 5.066 | 7.49 | 6.706 | -26.117 |
Non-Cash Items | 195.391 | -165.371 | 23.865 | 24.342 | 0.364 |
Cash Taxes Paid | 18.5 | -6.028 | 9.796 | 2.417 | 3.596 |
Cash Interest Paid | 9.798 | 5.429 | 3.465 | 4.49 | 2.279 |
Changes in Working Capital | 93.989 | -0.576 | -48.944 | -74.865 | 66.644 |
Cash From Investing Activities | -415.823 | -243.855 | -155.089 | -86.634 | -39.13 |
Capital Expenditures | -181.354 | -118.943 | -99.072 | -31.905 | -27.867 |
Other Investing Cash Flow Items, Total | -234.469 | -124.912 | -56.017 | -54.729 | -11.263 |
Cash From Financing Activities | -52.414 | 398.43 | 246.409 | 211.263 | -77.764 |
Financing Cash Flow Items | |||||
Issuance (Retirement) of Stock, Net | 0.699 | 404.322 | 251.564 | 1.901 | 1.578 |
Issuance (Retirement) of Debt, Net | -53.113 | -5.892 | -5.155 | 209.362 | -79.342 |
Foreign Exchange Effects | -19.04 | -0.066 | 9.505 | 1.134 | 2.692 |
Net Change in Cash | -284.171 | 276.746 | 145.546 | 167.979 | 42.038 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -175.655 | -148.454 | -101.179 | -73.242 | 215.51 |
Cash From Operating Activities | 203.106 | 236.633 | 240.607 | 63.618 | 122.237 |
Changes in Working Capital | 378.761 | 385.087 | 341.786 | 136.86 | -93.273 |
Cash From Investing Activities | -415.823 | -435.034 | -206.857 | -95.732 | -243.855 |
Capital Expenditures | -181.354 | -157.21 | -81.371 | -42.921 | -118.943 |
Other Investing Cash Flow Items, Total | -234.469 | -277.824 | -125.486 | -52.811 | -124.912 |
Cash From Financing Activities | -52.414 | -50.454 | -45.805 | -5.279 | 398.43 |
Issuance (Retirement) of Stock, Net | 0.699 | 0.355 | 0.7 | 0.345 | 404.322 |
Issuance (Retirement) of Debt, Net | -53.113 | -50.809 | -46.505 | -5.624 | -5.892 |
Foreign Exchange Effects | -19.04 | 13.442 | 9.721 | -1.445 | -0.066 |
Net Change in Cash | -284.171 | -235.413 | -2.334 | -38.838 | 276.746 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Novo Holdings A/S | Venture Capital | 9.8455 | 17444807 | -206374 | 2022-12-31 | LOW |
Government of Abu Dhabi | Government Agency | 6.5913 | 11678875 | 199342 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 5.0131 | 8882485 | 36011 | 2023-09-21 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 3.5645 | 6315718 | 2452073 | 2023-06-16 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.5926 | 4593730 | 1224 | 2023-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 2.2224 | 3937850 | 851779 | 2022-12-31 | LOW |
Brown Capital Management, LLC | Investment Advisor | 2.1752 | 3854173 | 18059 | 2023-03-31 | LOW |
Liontrust Investment Partners LLP | Investment Advisor | 2.0301 | 3597021 | -37024 | 2023-08-31 | LOW |
Allianz Global Investors GmbH | Investment Advisor | 1.84 | 3260133 | 10629 | 2023-08-31 | LOW |
Oetker (Roland) | Individual Investor | 1.639 | 2904146 | -5440854 | 2022-10-04 | LOW |
BlackRock Asset Management Deutschland AG | Investment Advisor | 1.5298 | 2710589 | -5722 | 2023-09-30 | LOW |
Franklin Equity Group | Investment Advisor | 1.2699 | 2250000 | 0 | 2023-09-30 | LOW |
Polar Capital LLP | Investment Advisor/Hedge Fund | 1.1488 | 2035438 | 0 | 2023-06-30 | LOW |
Deka Investment GmbH | Investment Advisor/Hedge Fund | 1.1055 | 1958807 | -3463 | 2023-09-30 | LOW |
California State Teachers Retirement System | Pension Fund | 1.0986 | 1946619 | 1704482 | 2022-06-30 | LOW |
Evotec SE Management | Corporation | 0.9987 | 1769527 | 0 | 2022-12-31 | LOW |
DWS Investment GmbH | Investment Advisor/Hedge Fund | 0.8748 | 1549952 | 4235 | 2023-09-30 | LOW |
Baillie Gifford & Co. | Investment Advisor | 0.7134 | 1263957 | -38325 | 2023-08-31 | LOW |
T. Rowe Price International Ltd | Investment Advisor/Hedge Fund | 0.6168 | 1092871 | -24740 | 2023-09-30 | LOW |
Lupus alpha Asset Management AG | Investment Advisor/Hedge Fund | 0.5858 | 1038000 | -105000 | 2023-06-30 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Evotec Company profile
About Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Evotec SE revenues increased 20% to EUR431M. Net income increased from EUR5.8M to EUR247M. Revenues reflect EVT Execute segment increase of 22% to EUR329M, EVT Innovate segment increase of 36% to EUR101.9M, United States segment increase of 32% to EUR142.9M, Others segment increase of 30% to EUR47.5M, United Kingdom segment increase of 8% to EUR47.2M.
Industry: | Biotechnology & Medical Research (NEC) |
Essener Bogen 7
HAMBURG
HAMBURG 22419
DE
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com